Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-0105
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination ; volume:7 ; number:1 ; day:15 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
npj vaccines ; 7, Heft 1 (15.11.2022), 1-8, 12.2022
- Creator
-
Byazrova, Maria G.
Astakhova, Ekaterina A.
Minnegalieva, Aygul R.
Sukhova, Maria M.
Mikhailov, Artem A.
Prilipov, Alexey G.
Gorchakov, Andrey A.
Filatov, Alexander V.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-022-00566-x
- URN
-
urn:nbn:de:101:1-2023012809343628802686
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Byazrova, Maria G.
- Astakhova, Ekaterina A.
- Minnegalieva, Aygul R.
- Sukhova, Maria M.
- Mikhailov, Artem A.
- Prilipov, Alexey G.
- Gorchakov, Andrey A.
- Filatov, Alexander V.
- SpringerLink (Online service)
Other Objects (12)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Vac
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
Compromise Rejected.
A Compromise.
No Compromise
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Vac
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
Compromise Rejected.
A Compromise.
No Compromise
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Vac
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
Compromise Rejected.
A Compromise.
No Compromise
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster